ABSTRACT
VERNAL KERATOCONJUNCTIVITIS
VKC is a severe inflammatory disease that appears in children and adolescents with seasonal recurrence. It is most often seen in boys and tends to resolve at puberty. It is a relatively rare, chronic form of ocular allergy that can cause severe visual complications [2] [3] [4] .
VKC is more frequent in warmer, arid, windy climates, in the Mediterranean area, central [12] [13] [14] . The recommended dosing schedule is 4-6 times daily, with a loading period of at least 7 days and an onset of activity after as much as 2 weeks. DSCG alone has limited effects in the treatment of VKC and is less well tolerated than newer anti-allergic compounds. Nedocromil appears to be more potent than DSCG [15] , acting on multiple cells involved in allergic Lodoxamide has long been available for the treatment of VKC. Its mechanism of action is thought to be similar to that of DSCG, since it was shown to prevent tryptase release [16] . Lodoxamide was shown to be more effective than DSCG for the inhibition of eosinophil activation, evaluated by measuring tear eosinophil cationic protein ECP before and after therapy [17] , suggesting that lodoxamide has an effect on eosinophil activation. Inhibition of eosinophil activation and degranulation is the proposed mechanism for its efficacy against corneal signs such as keratitis and shield ulcers in severe allergic disease [17] . Lodoxamide was shown to be superior to placebo [18] and N-acetyl aspartyl glutamic acid (NAAGA) for treatment of VKC [19] . The recommended dosing schedule is four times daily. Lodoxamide may be used continuously for 3 months in children older than 2 years of age.
NAAGA 6% has been widely used in Europe as topical eye drops in the treatment of VKC [20] . NAAGA is known to inhibit leukotriene synthesis, histamine release by mast cells, and complement-derived anaphylatoxin production. This anti-allergic compound was also shown to directly inhibit leukocyte adhesion to endothelial cells induced by proinflammatory stimuli, and abrogates tumor necrosis factor a-induced expression of adhesion molecules on granulocytes and endothelial cells [21] . These pharmacological properties confer a potential anti-inflammatory activity.
Antihistamines

Antihistamines act via histamine receptor (HR)
antagonism to block the inflammatory effects of endogenous histamine and prevent or relieve the associated signs and symptoms. Most antihistamines used in the treatment of allergy are H 1 receptor antagonists, although some agents may have affinity for other receptor subtypes [22] . H 2 antagonists have been shown to modulate both cell growth and migration [22] . Ocular drugs with antihistaminic activity may offer therapeutic advantages to patients with allergic conjunctivitis, including VKC, by inhibiting proinflammatory cytokine secretion from conjunctival epithelial cells [23] . The firstgeneration antihistamines pheniramine and antazoline have a long safety record, but are known for their burn upon instillation, the rapid onset and disappearance of their effects, and their limited potency [24] . These are still available in over-the-counter products, particularly in combination with vasoconstrictors.
The newer antihistamines are still H 1 antagonists, but have a longer duration of action (4-6 h), and are better tolerated than their predecessors. These include levocabastine hydrochloride 0.5% and emedastine difumarate 0.05%.
Levocabastine 0.05% eye drops alone, instilled four times daily for 3 months, was effective, safe, and well tolerated by patients with VKC; however, it was less effective than lodoxamide [25] or NAAGA [20] . Interestingly, in an animal model, levocabastine reduced the clinical aspects of the late-phase reaction and the conjunctival expression of alpha (4) A meta-analysis of randomized clinical trials in VKC showed a large number of studies (20) evaluated the efficacy of common anti-allergic eye drops (levocabastine, lodoxamide, mipragoside, NAAGA, nedocromil sodium, DCG). Among these, lodoxamide appeared to be the most effective [10] . Steroid-antibiotic combination eye drops should be avoided, as VKC is an allergic inflammation, rather than an infection.
Corticosteroids should not be recommended for long-term use because of possible ocular adverse effects, including increases in intraocular pressure (IOP), induction or exacerbation of glaucoma, formation of cataracts, delayed wound healing, and increased susceptibility to infection or superinfection. These adverse effects depend, in part, on the structure, dose, duration of treatment and gender disposition [36] . In fact, following daily administration of corticosteroids for 4-6 weeks, approximately one-third of the normal population will be ''high or moderate responders'' with an increase in IOP of between 6 and 15 mm Hg [36] . Forty-one of 145 (28.3%) patients with severe VKC in a Singapore case series developed a corticosteroid response, of which eight (5.5%) progressed to glaucoma [37] . Six of these patients (n = 8 eyes) required trabeculectomy/mitomycin-C. The main risk factor for trabeculectomy was a greater increase in IOP from baseline, which was independent of potential confounders such as type and duration of corticosteroid use [38] .
Calcineurin Inhibitors and Other
Immunomodulators Cyclosporine A (CsA) is effective in controlling VKC-associated ocular inflammation by blocking Th2 lymphocyte proliferation and interleukin-2 production. It inhibits histamine release from mast cells and basophils through a reduction in IL-5 production, and may reduce eosinophil recruitment and effects on the conjunctiva and cornea [39] . CsA is lipophilic and thus must be dissolved in an alcohol-oil base [39] . Unavailability of a commercial preparation of topical CsA, technical difficulties in dispensing eye drops and legal restrictions on its topical use in many countries, preclude its widespread use for VKC treatment.
The 2% formulation has the longest track record, but lower concentrations (1%, 0.5%, and 0.05%) have been used and shown to be effective. So far, there is no general consensus regarding the minimum effective concentration of CsA. Only the 0.05% formulation is commercially available for the treatment of dry eye.
After long cycles of treatment, CsA has a marked steroid-sparing effect, potentially allowing control of symptomatology without steroids [40] . When necessary, additional topical steroids can be used in short cycles. CsA 1% or 2% emulsion in castor or olive oil instilled four times daily can be considered for treatment of moderate to severe VKC and can serve as a good alternative to steroids [39, 41] .
After 2 weeks, CsA 1% four times daily significantly reduced signs and symptoms and tear levels of ECP in a group of VKC patients [42] .
CsA 1% was reported to be the minimum effective concentration in the treatment of shield ulcers, with recurrence observed at lower concentrations [43] . In a randomized, controlled trial, the effects of CsA 0.05% were similar to placebo [44] . improved. The most frequent tacrolimusrelated adverse event was ocular irritation [52] .
In the same study it is also reported that the dose of tacrolimus was based on the results from a previous dose-ranging study in which tacrolimus ophthalmic suspension 0.01%, 0.03%, and 0.1% were tested. Since 0.1%
showed stronger improvement and similar safety profile compared with 0.01% and 0.03%, the 0.1% was considered an optimal dose.
Documentation on the quality, safety and efficacy of the different preparations used in the different clinical reports will be necessary before tacrolimus is granted orphan medication status for VKC.
A prospective double-masked randomized comparative trial comparing the efficacy of 0.1% tacrolimus ophthalmic ointment with CsA 2% showed that both were equally effective in the treatment of VKC [53] .
Short-term, low-dose, topical mitomycin-C 0.01% has been considered for treating acute exacerbations in patients with severe VKC refractory to conventional treatment [54] . A significant decrease in signs and symptoms compared with the placebo group was shown at the end of the 2-week treatment period.
Unavailability of commercial topical preparations, the short duration of studies, and the lack of data on the safety profile and long-term outcomes are major limitations in recommending mitomycin for the treatment of VKC.
Topical Non-Ocular Pharmacologic Treatment
The efficacy of intranasal corticosteroids in treating allergic nasal symptoms is well 
Systemic Pharmacologic Treatment
Systemic treatment with oral antihistamines or antileukotrienes can reduce the severity of flare-ups and generalized hyper-reactivity. Firstgeneration H 1 receptor antagonists may provide some relief of ocular itching, but are sedating and have anticholinergic effects such as dry mouth, dry eye, blurred vision and urinary retention.
Second-generation antihistamines offer the same efficacy as their predecessors, but with a lowsedating profile and lack of anticholinergic activity. These drugs include acrivastine, cetirizine, ebastine, fexofenadine, loratadine and mizolastine. However, even their use has been associated with drying effects, particularly of the ocular surface [58] . Desloratadine and levocetirizine are considered a subsequent evolution of these second-generation agents and are preferred over first-generation antihistamines for the treatment of allergic conjunctivitis [59] .
Aspirin 0.5-1 g per day has been shown as a steroid-sparing factor in the treatment of VKC [60] ; however, it should be used with caution because of the well-known possible side effects.
In severe cases, systemic treatment with T-lymphocyte signal transduction inhibitors such as CsA or tacrolimus may ameliorate both the dermatologic and ocular manifestations in severe patients who are refractory to conventional treatment [61] . Omalizumab, an anti-IgE recombinant, humanized, non-anaphylactogenic antibody, directed against the receptor-binding domain of IgE, may be used in VKC patients with high levels of total serum IgE [62] .
Specific Immunotherapy
Allergen-specific immunotherapy (SIT) is indicated only when a clearly defined systemic hypersensitivity to identified allergens exists.
The choice of the allergen to be employed for SIT should be made in accordance with the combination of clinical history and results of skin prick test and specific serum IgE. Since the development of non-invasive formulations with better safety profiles, there is an increasing tendency to prescribe sublingual immunotherapy (SLIT) in young patients. A systematic review and meta-analysis of double-blind, placebo-controlled randomized controlled trials confirmed that SLIT reduces significantly ocular symptom scores in patients with allergic conjunctivitis with or without rhinitis [63] . The SIT treatment in IgE-positive patients with VKC was more effective than topical treatment in improving clinical symptoms and reducing total serum IgE [64] .
Surgical Treatment
Supratarsal injection of either a short-or intermediate-acting corticosteroid has been proposed as a therapeutic approach to treating patients with refractory VKC [65] . Although significant symptomatic and clinical improvements have been reported, persistent increase in IOP occurred in one of 12 VKC patients [65] . Surgical removal of corneal plaques is recommended to alleviate severe symptoms and to allow for corneal re-epithelization. Giant papillae excision with intraoperative 0.02% mitomycin-C followed by CsA topical treatment may be indicated in cases of mechanical pseudoptosis or the presence of coarse giant papillae and continuous active disease [66, 67] .
Cryotherapy and/or excision of giant papillae should otherwise be avoided because these measures treat only the complications and not the underlying disease, and may induce unnecessary scarring. Amniotic membrane transplantation (AMT) following keratectomy has been described as a successful treatment for deep ulcers, in cases with slight stromal thinning [68] . The presence of residual membrane under the epithelium may affect postoperative corneal transparency. The treatment algorithm for corneal complication can be based on the Cameron clinical grading of shield ulcers [69] : Grade 1, ulcers received medical therapy alone; Grade 2 and Grade 3 ulcers received either medical therapy alone or medical therapy combined with debridement, AMT, or both. Using this approach, it was shown that Grade 1 ulcers respond well to medical therapy alone; Grade 2 ulcers occasionally may require additional debridement or AMT; Grade 3 ulcers are frequently refractory to medical therapy and require debridement and AMT for rapid re-epithelialization [70] .
Significant limbal stem cell deficiency as a complication of severe and persistent limbal inflammation has been treated with stem cell transplantation [71, 72] .
These and other more invasive procedures such as oral mucosal grafting should be avoided or considered only by ophthalmology experts in VKC management.
PRACTICAL MANAGEMENT OF VKC
Treatment of VKC requires a multi-pronged approach that includes conservative measures and the use of drugs, as summarized in Table 3 .
Close collaboration between ophthalmologists, allergists and pediatricians is recommended.
Patients and parents should be made aware of the long duration of disease, its chronic evolution and possible complications.
It is recommended to use a clinical grading system to identify the more severe forms of VKC that are at higher risk of recurrences, corneal ulceration, and worsened final visual outcome [73] . A simple grading system has been proposed to formulate global guidelines for treating VKC (Table 4) 
